Pharma News India Weekly (05 April – 11 April 2026): GLP-1 War, Sun Pharma Deal Buzz, Govt Secures Supply Chains

The week of April 5 to April 11, 2026, has delivered another set of high-voltage developments for the Indian pharmaceutical industry. From Eli Lilly losing market share to generic semaglutide, to Sun Pharma reportedly eyeing a massive acquisition, and the government stepping in to secure LPG supplies—this week had it all.

As the patent cliff accelerates and geopolitical tensions persist, Indian pharma companies are adapting fast. Let's dive into the week's biggest stories.

APPLY FOR PCD PHARMA FRANCHISE

Top 8 Headlines This Week (05-11 April 2026)

Eli Lilly's Mounjaro Loses Ground: Within days of generic semaglutide launch, Mounjaro's market share dropped from 71% to 64%.
Sun Pharma-Organon Mega Deal Buzz: Reports suggest Sun Pharma is close to acquiring US-based Organon for approximately $12 billion.
Government Secures Pharma Feedstock: LPG allocation for pharma increased to 70% with a 200 tonnes/day cap.
Aurobindo Announces ₹800 Crore Buyback: Fixed April 12 as record date for share buyback at ₹1,475 per share.
Cancer Drug Price Hike Sought: Manufacturers approached NPPA seeking 50% increase for platinum-based cancer drugs.
AstraZeneca to Sell Bengaluru Facility: Plans to offload 64-acre site for estimated ₹3,400 crore.
Government Bans Private Labs for Vaccine Testing: Move to restrict biological product testing to government laboratories.
Biocon Aims for Global Insulin Leadership: Kiran Mazumdar-Shaw says company targets 20% of global insulin market.

1. GLP-1 Market Shakeup: Generics Dent Eli Lilly's Dominance

The most significant story in latest pharma news this week is the rapid erosion of Eli Lilly's Mounjaro market share following the semaglutide patent expiry on March 20.

Mounjaro Sales Drop 15% in March

According to data from market research firm Pharmarack, Mounjaro (tirzepatide) sales declined to ₹114 crore in March 2026 from ₹135 crore in February—a drop of 15%. Meanwhile, semaglutide-based drugs (both innovator and generics) saw sales rise 23% month-on-month to ₹59 crore.

GLP-1 Market Share (March 2026): Mounjaro 64% (down from 71%), Semaglutide 33% (up from 25%)
Eli Lilly's value share fell from 61% in February to 56% in March
13 companies launched 26 generic semaglutide versions within days of patent expiry
The GLP-1 market in India is now approximately ₹1,600 crore in size

"Participation is high, but value capture will be concentrated among top three to four players," said Sheetal Sapale, VP-Commercial at Pharmarack.

Torrent Emerges as Top Generic Player

Among domestic players, Torrent Pharmaceuticals has emerged as the largest generic semaglutide player after Novo Nordisk, holding 8% market share. Other active players include Sun Pharma (Noveltreat, Sematrinity), Dr. Reddy's (Obeda), Zydus Lifesciences, Lupin, and Glenmark (Glipiq).

Novo Nordisk Holds Its Ground

Despite the generic onslaught, Novo Nordisk maintained its position through aggressive price cuts (48% on Wegovy, 36% on Ozempic) and strong physician relationships. The company's starting dose (0.25mg) is now priced at ₹5,660 per month—keeping it competitive with generics.

2. Sun Pharma-Organon: A $12 Billion Mega Deal?

The biggest corporate news this week revolves around Sun Pharmaceutical Industries reportedly eyeing a massive acquisition.

What the Reports Say

According to The Economic Times and other publications, Sun Pharma is in advanced talks to acquire Organon—the US-based women's health company spun off from Merck (MSD)—in a deal valued at approximately $12 billion. The all-cash offer would be Sun's largest acquisition ever.

Organon's market cap stood at $1.52 billion in Thursday morning trade
Sun Pharma has about $3.2 billion (₹26,000 crore) of net cash on its balance sheet
The company would likely raise debt to fund the remainder

Sun Pharma's Response

In a clarification to stock exchanges, Sun Pharma called the reports "speculative in nature" and stated there was "no material event/information that requires disclosure." However, analysts note that Chairman Dilip Shanghvi had previously told investors the company was looking for "disciplined" acquisitions.

Why Organon Makes Sense

Organon focuses on women's health, biosimilars, and established products. It has flagship brand Nexplanon (etonogestrel implant) which posted $921 million in 2025 sales. The acquisition would give Sun Pharma:

A stronger foothold in the US women's health market
A biosimilar portfolio to bolster its innovation pipeline
Immediate scale in regulated markets

However, Organon carries approximately $8 billion in debt, making this a high-stakes bet. Sun Pharma's shares closed down nearly 4% at ₹1,654.70 on BSE following the news.

3. Government Secures Pharma Supply Chains Amid West Asia Crisis

The ongoing West Asia conflict continues to disrupt raw material supplies, but the government has stepped in with multiple relief measures this week.

LPG Allocation Increased to 70%

The Ministry of Petroleum and Natural Gas increased LPG allocation to 70% for industrial units in pharmaceuticals, food, polymers, agriculture, packaging, ceramics, and glass sectors. The allocation is capped at 200 tonnes per day per sector.

Industrial units will receive 70% of their pre-March 2026 bulk non-domestic LPG consumption
Units using LPG as an integral input are exempt from switching to PNG
Priority given to industries where LPG cannot be substituted by natural gas

Customs Duty Exemption Continues

The government has already removed customs duty on 40 petrochemical products through an April 1 notification. This covers critical inputs like propylene, ammonia, methanol, phenol, and isopropyl alcohol.

Domestic Refiners Step Up

Indian refiners including Bharat Petroleum have reconfigured production lines to supply specialized feedstock to pharma companies. Propylene—the most critical feedstock—is now being supplied domestically for intermediates used in medicines like Ibuprofen.

Pharma Supply Chains May Take Months to Heal

Despite the ceasefire between US and Iran, industry experts warn that supply chains will take months to stabilize. Pharmexcil Chairman Namit Joshi said it will take "at least a month or two to bring raw material prices back to normal." The West Asia region accounts for 5-6% of India's total pharmaceutical exports.

4. Cancer Drug Makers Seek 50% Price Hike

Local manufacturers of platinum-based cancer drugs have approached the National Pharmaceutical Pricing Authority (NPPA) seeking a 50% increase in ceiling prices.

The Problem

Platinum prices have nearly doubled in the last six months—from ₹3,869 per gram in September 2025 to approximately ₹8,000 per gram in February 2026. This has made manufacturing of drugs like carboplatin, oxaliplatin, and cisplatin commercially unviable.

Current ceiling price for carboplatin: ₹61.10 per 10mg/ml vial
Cisplatin price range: ₹70 to ₹300 based on strength
Top manufacturers include Cipla, Intas, Dr. Reddy's, Zydus, Emcure, Fresenius, and Hetero

Why This Matters

Platinum-based drugs form the backbone of treatment for multiple cancers including head and neck, breast, and gastrointestinal cancers. As Dr. Pramod Kumar Julka (Max Oncology Vice Chairman) noted, these are "among the most affordable and widely accessible chemotherapy agents available."

The paradox is that their low price now threatens their availability. "Manufacturers have little financial incentive to produce them reliably," an industry executive said.

Historical Context

Platinum-based drugs have been under price control since 2013. For carboplatin, the price increase since 2015 is just 21.71% (2.21% CAGR). The Niti Aayog's Committee on Affordable Medicines had endorsed a one-time 50% increase for essential medicines facing manufacturing unviability back in 2019.

5. Aurobindo Pharma Announces ₹800 Crore Share Buyback

Hyderabad-based Aurobindo Pharma fixed April 12, 2026 as the record date for its ₹800 crore share buyback.

Key Details

Buyback price: ₹1,475 per share
Number of shares: Up to 54.23 lakh equity shares (0.93% of paid-up capital)
Method: Tender offer route on proportionate basis
Eligibility: All shareholders including promoters holding shares on record date

Company Performance

Aurobindo's stock has shown resilience, gaining nearly 9% in a month compared to a 4.3% fall in the ET Pharma Index. The company's Europe business remains strong (31% of revenue in December quarter vs 27% in FY25), and its US business is expected to pick up led by sterile capacity ramp-up.

Motilal Oswal Financial Services expects Aurobindo to deliver 21% earnings growth annually over FY26-28 and has maintained a Buy rating with a target price of ₹1,500.

6. AstraZeneca to Sell Bengaluru Facility for ₹3,400 Crore

AstraZeneca Pharma India is planning to sell its 64-acre manufacturing facility in North Bengaluru as part of a global review of its manufacturing network.

The Deal

Expected value: Approximately ₹3,400 crore (over ₹53 crore per acre)
Interested buyers: Sattva Group, Aurobindo Pharma, and RMZ
The company wants to exit with scope for commercial/residential development

Background

The Bengaluru facility is one of nine global sites of AstraZeneca focused on clinical trial design, safety monitoring, and regulatory compliance. The company was established in India in 1979.

The divestment comes amid a broader trend of companies monetizing non-core land assets, driven by rising land values in key cities. Developers are actively acquiring such parcels, with players like Godrej Properties and Prestige Group leading transactions.

7. Government to Restrict Vaccine Testing to Government Labs

In a major policy shift, the Central Drugs Standard Control Organisation (CDSCO) plans to restrict testing of vaccines and biological products exclusively to government-controlled laboratories.

The Rationale

"The specialized nature of vaccines warrants a more restrictive testing environment," a government official said. The move aims to bring uniformity across all testing platforms and follows criticism of lax oversight.

Current setup: 7 Central Drug Testing Laboratories and 36 state drug testing laboratories
Private sector: 350-400 standalone labs approved for drug testing, but only a small fraction have high-level biosafety certification for vaccines

Impact on Industry

Major vaccine manufacturers including Serum Institute of India (world's largest by doses), Bharat Biotech, Biological E, and Zydus Lifesciences will be affected.

Dr. Vikram Paradkar (Executive VP-Vaccines at Biological E) noted that every single batch of the company's vaccines is already tested at its own quality control facilities and submitted to the National Control Laboratory at Kasauli. "Thus, there is no change to existing practice," he said.

Public Health Context

In FY25, 3,104 drug samples were declared Not of Standard Quality (NSQ), and 245 were found to be spurious. Biologics including monoclonal antibodies and hormones are currently tested at the National Institute of Biologicals in Noida.

8. Biocon Aims for Global Insulin Leadership

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, made a bold statement this week: Biocon aims to be "the" insulin company of the world.

The Opportunity

Global pharmaceutical majors are shifting focus toward high-margin GLP-1 therapies, creating an opening in the insulin market.

"Big insulin companies do not want to make insulin in cartridges or pens anymore. They are switching to selling insulin in vials, as they wish to focus on the GLP-1 opportunity," Mazumdar-Shaw said.

Biocon's Position

Third-largest supplier of both rh-Insulin and Insulin Glargine worldwide
Only company in the world with two interchangeable insulins
Over 9.2 billion doses of insulin provided worldwide
Approvals across 80 countries

The Target

"Our aim is to achieve 20% market share in the global insulin market," said Shreehas Tambe, CEO and MD of Biocon.

The company is expanding insulin capabilities and has identified 20 emerging markets as growth markets. Biocon already reaches one in five insulin-dependent patients in the US.

IPO Framework Concerns

Mazumdar-Shaw also called for a rethink of India's IPO framework, arguing that current norms requiring three years of revenue track record are ill-suited for clinical-stage biotech companies. "In the US, you can do all this. In India, Sebi requires three years of revenue track-record. How does a clinical-stage biotech ever meet that?" she asked.

9. Other Important News (Brief)

Granules India Increases FDA Compliance Oversight

Following USFDA observations at its Telangana plant (violations in GMP, equipment cleaning, contamination controls), Granules India is increasing oversight and digitizing documents at its manufacturing facilities.

Natco Pharma Breakout Anticipated

Technical analysts expect Natco Pharma stock to break out above ₹1,050, with a medium-term target of ₹1,600. The stock has been trading sideways between ₹750 and ₹1,050 for the past year.

Pharma Exports at ₹28.29 Billion (April-February FY26)

Pharmexcil reported 5.6% growth in pharma exports during April-February FY26. The sector is currently valued at $60 billion and projected to reach $130 billion by 2030.

Fake Medicine Racket Busted in Delhi

Delhi Police busted a racket supplying spurious life-saving medicines with fake packaging of big pharma firms. Six people were arrested, and over 1.20 lakh counterfeit tablets were recovered, including fake versions of Telma-AM, Ursocol-300, and Montair-LC.

FAQ: Your Questions Answered

Q: What are the top pharmaceutical trends for 2026?

A: Based on this week's news, the top trends include: 1) GLP-1 market disruption with generics rapidly capturing share from innovators. 2) Consolidation through M&A (Sun Pharma-Organon talks). 3) Supply chain localization amid geopolitical tensions. 4) Biosimilar and insulin expansion (Biocon's global ambitions). 5) Regulatory tightening on vaccine testing and excipient tracking. 6) Price pressures on essential cancer drugs due to raw material cost spikes.

Q: What are the latest pharma news updates this week (05-11 April 2026)?

A: Key updates include: Eli Lilly's Mounjaro losing market share to generic semaglutide; Sun Pharma reportedly in talks to buy Organon for $12 billion; Government increasing LPG allocation to 70% for pharma; Cancer drug makers seeking 50% price hike; Aurobindo announcing ₹800 crore buyback; and AstraZeneca planning to sell Bengaluru facility for ₹3,400 crore.

Q: Where can I find all weekly pharma industry news?

A: For comprehensive, curated weekly updates covering policy changes, market trends, and company-specific news in the Indian pharmaceutical sector, you can rely on Greenncrossindia.com/blog.

Q: What is happening in the pharmaceutical industry this week?

A: The industry is navigating multiple challenges simultaneously: a price war in the GLP-1 segment (good for patients, challenging for innovators), supply chain disruptions from the West Asia conflict (government stepping in with LPG allocations), potential mega-deal activity (Sun Pharma-Organon), and regulatory changes affecting vaccine testing and drug approvals.

Weekly Summary: Key Points

GLP-1 Market: Generic semaglutide has captured 33% of the market within weeks, with Mounjaro's share dropping to 64%. Torrent leads among domestic players.
M&A Activity: Sun Pharma is reportedly in advanced talks to acquire Organon for $12 billion—its largest deal ever.
Supply Chain Relief: Government increased LPG allocation to 70% for pharma and maintained customs duty exemptions on 40 petrochemical products.
Cancer Drugs: Manufacturers seek 50% price hike for platinum-based drugs as raw material costs have nearly doubled.
Regulatory Shift: Vaccine testing to be restricted to government laboratories only, impacting private labs.
Biocon's Ambition: Aiming for 20% of global insulin market as big pharma shifts focus to GLP-1.
Exports: Pharma exports grew 5.6% to $28.29 billion in April-February FY26, though FY26 target may be missed.

This weekly news update is compiled from multiple sources including The Economic Times, Business Line, Mint, Financial Express, Business Standard, and Pharmarack data. For weekly updates and deeper analysis, visit Greenncrossindia.com/blog.

Disclaimer: This weekly news roundup is compiled from various publicly available sources including news publications, industry reports, and regulatory announcements. The information provided is for informational and educational purposes only and does not constitute medical advice, investment advice, or any professional recommendation. Readers are advised to consult qualified medical professionals before making any healthcare decisions and to conduct their own research before making any investment decisions. Greencrossindia.com does not guarantee the accuracy or completeness of the information presented.